India
More than a dozen semaglutide generics hit the Indian market at sharp discounts post LOE for Novo Nordisk’s GLP-1 RA molecule setting the stage for a high-octane battle in the diabetes and obesity segment. Can Novo hold steady amid the avalanche and what are KOLs looking for?
Natco has announced a 90% difference in the price of its semaglutide generic in multi-dose vials versus originator Novo Nordisk’s Ozempic pen ahead of launch tomorrow as Novo’s patents on the product expire today. Its pen will be 70% cheaper.
After creating a new biosimilars unit, Sandoz is now divesting its generics portfolio in Sub-Saharan Africa to the Strides Pharma group. Strides will acquire or license these brands for an initial $12m plus royalty, placing it among the top five firms in the region
Zydus’s investment in a differentiated drug-device combination for semaglutide has led to a win-win GLP-1 co-marketing deal with Lupin even as the Indian drug regulator keeps a watch on advertising activities
India issues firm advisory on promos for obesity and metabolic disorders therapies ahead of loss of exclusivity for semaglutide later this week, with 50-plus generic brands seen in the wings for a share of the pie. Will Eli Lilly and Novo Nordisk have to tweak their multimedia campaigns?
Parexel’s CEO Peyton Howell and India chief Sanjay Vyas talked to Scrip about trials amid global upheavals, the slowdown in big pharma decision-making and pivot in some cases to the FSP model, an evolving DCT definition and India opportunities.
CRDMOs must embrace AI to keep pace with big pharma partners - but what is expected of them, which data can they use, where are Indian firms on the adoption curve and does the ‘China Plus One’ business proposition still hold? Leaders discussed these topics at BioAsia.
India pharma leaders emphasize the need for AI integration beyond pilots, calling for an enterprise mindset to drive AI adoption and a focus on re-skilling for ‘everyone’. Discussions touched on AI’s role in driving manufacturing efficiencies and also India’s innovation trajectory.
Sanofi’s EVP Madeleine Roach details ways in which snackable, generative and expert AI are transforming innovation, helping halve the time for a drug to move from discovery to market. AI has aided a cut in mRNA design time by 50% at the "first AI-powered biopharma at scale."
Google DeepMind’s vice-president, Science and Strategic Initiatives, talks about the potential of the group’s new generation of AI models designed to address problems across biology, heralding a new era of science and medical advances.
Pioneering immunologist, Prof. Bruce Levine from UPenn, wears his passion for CAR-T cell therapy on his sleeve as he highlights future uses of the therapy, predictive markers and off-the-shelf CAR-T while speaking about a journey from Kymriah co-inventor to country music co-writer
Novartis divests listed India entity but maintains country commitment intact, portfolio expansions underway.
MSD’s Chief AI Officer talks about how AI is reshaping R&D, enabling the company to double its molecules in discovery, foundational models and leading 'differently' in the age of AI.
Aurobindo has pushed its projection of an inflection point for biosimilars ahead by a year to FY29 but plans to launch a generic to BMS blockbuster Pomalyst (pomalidomide) in the current quarter. Meanwhile, anti-competitive pricing of penicillin-G by China should now cause less harm
Do Zydus and Lupin’s settlements of Myrbetriq (mirabegron) US patent litigation with Astellas constitute a win or a loss?
Indian industry stalwarts discuss taking a leaf out of China’s book to lead in biopharma innovation, call for “greater acceptability” of indigenously developed therapies and reflect on the historical struggle for changes in India's patent laws, including an incident that jolted a prime minister.
Following a $90m settlement with Astellas over Myrbetriq (mirabegron) in the US, Lupin can continue selling its generic product even as Zydus says the Delaware district court has directed mediation but the trial is proceeding. How have the generics fared and what does this mean now?
The US-India dance around pharma goes on as they announce a trade deal framework that continues to exempt generics from the reduced 18% tariffs till a “negotiated outcome” is reached post a Sec. 232 investigation. However, oil imports from US could increase costs for Indian pharma firms
India’s budget backs plans to scale production of biologics and biosimilars, shore up its clinical trials network and strengthen the regulatory framework. Customs duty exemptions given to several big pharma therapies, including those of Novartis and Takeda.
Strides Pharma aims for higher revenues from Canada and other ex-US markets while waiting for controlled substances to ramp up gradually under the leadership of ex-Apotex CEO Peter Hardwick. However, a cut in US funding for the Global Fund is hurting the company and its competitors.